In This Issue
Cancer Discov October 1 2019 9 (10) 1325-1328; DOI:10.1158/2159-8290.CD-ITI9-10
The locations of mutations in APC, which hyperactivate WNT signaling and are common in colorectal cancers, dictate whether tankyrase inhibition can restore normal WNT signaling.
A phase I/II clinical trial of the PARP inhibitor olaparib with the DNA-alkylating agent temozolomide in small-cell lung cancer provided preliminary evidence of efficacy, and a co-clinical trial using patient-derived xenografts revealed possible biomarkers for response.
Biomarker-based treatment of patients with gastric cancer was associated with an improved overall response rate, and patients with MET amplifications who received savolitinib exhibited especially promising responses.
Single-cell analysis of Langerhans cell histiocytosis lesions revealed cellular and molecular heterogeneity suggestive of a developmental hierarchy shared among lesions.
The counterintuitive response of some PD-L1- tumors to anti–PD-L1 therapy may be a result of PD-L1 expression on natural killer (NK) cells, which can be triggered by contact between NK cells and myeloid leukemia cells.
Mutations in the bodies of core histone proteins recur in cancers; the most common one (H2BE76K) destabilizes nucleosomes, increases chromatin accessibility, alters gene expression, and increases proliferation of normal epithelial cells.
Recurrent and lineage-specific mutations in the nuclear-export receptor XPO1 alter the distribution of proteins in the nucleus and cytoplasm and promote oncogenesis in vitro and in vivo.